<DOC>
	<DOCNO>NCT02954341</DOCNO>
	<brief_summary>The purpose Post Approval Study ( PAS ) evaluate use CardioMEMS HF System patient Class III Heart Failure commercial setting .</brief_summary>
	<brief_title>CardioMEMS HF System OUS Post Approval Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Written inform consent obtain subject &gt; 18 year age Diagnosis NYHA Class III Heart Failure At least 1 HF hospitalization within 12 month Baseline visit Subjects reduce LVEF heart failure receive beta blocker 3 month ACEI ARB one month unless investigator 's opinion , subject intolerant beta blocker , ACEI ARB . Subjects willing able comply followup requirement study Subjects active infection Subjects history recurrent ( &gt; 1 ) pulmonary embolism deep vein thrombosis Subjects , Investigator 's opinion , unable tolerate right heart catheterization Subjects major cardiovascular event ( e.g. , myocardial infarction , open heart surgery , stroke , etc . ) within 2 month Baseline Visit Subjects Cardiac Resynchronization Device ( CRT ) implant &lt; 3 month prior enrollment Subjects Glomerular Filtration Rate ( GFR ) &lt; 25 ml/min ( obtain within 2 week baseline visit ) nonresponsive diuretic therapy chronic renal dialysis Subjects congenital heart disease mechanical right heart valve ( ) Subjects likely undergo heart transplantation VAD within 6 month baseline visit Subjects know coagulation disorder Subjects hypersensitivity allergy aspirin , and/or clopidogrel ( applicable subject take anticoagulation therapy approve antiplatelets therapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>